Senores Pharmaceuticals · NSE: SENORES · BSE: 544319
Q1 FY26 results · Apr–Jun 2025
Senores Pharmaceuticals reported revenue from operations of ₹137.99 crore and net profit of ₹21.18 crore for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 137.99 | — | — | 114.21 | +20.8% |
| Other income | 3.36 | — | — | 11.77 | −71.5% |
| Total income | 141.35 | — | — | 125.98 | +12.2% |
| Profit before tax | 26.49 | — | — | 20.68 | +28.1% |
| Net profit for the period | 21.18 | — | — | 17.97 | +17.9% |
| Attributable to shareholders of the company | 19.73 | — | — | — | — |
| EPS, basic (₹) | 4.60 | — | — | 3.81 | +20.7% |
| Net margin (%) | 15.3 | — | 15.7 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 19.82 | — | — | 11.86 | +67.1% |
| Other income | 8.39 | — | — | 9.25 | −9.3% |
| Total income | 28.21 | — | — | 21.11 | +33.6% |
| Profit before tax | 3.59 | — | — | 2.90 | +23.8% |
| Net profit for the period | 2.70 | — | — | 2.02 | +33.7% |
| EPS, basic (₹) | 0.59 | — | — | 0.39 | +51.3% |
| Net margin (%) | 13.6 | — | 17.0 |
Consolidated
- Filed with BSE
- 25 Jul 2025, 12:54 IST
- Board meeting
- 23 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 Jul 2025, 12:54 IST
- Board meeting
- 23 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE